Immatics Announces Full Year 2023 Financial Results and Corporate Update
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
Anabolika können Risiko von Vorhofflimmern bei Veranlagung erhöhen Neuronen im Gehirn können den Puls fühlen Bewegungsen…
Bayer zeigt fortlaufendes Engagement bei der Behandlung von Prostatakrebs und präsentiert weitere Daten zu Darolutamid a…
RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous…
Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program…
Preclinical data published in Frontiers in Immunology, a leading peer-reviewed journal Induction of pro-inflammatory…
Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA2…
ACTengine® IMA203 TCR-T monotherapy against PRAME showed 50% confirmed objective response rate (cORR) at or above target…
Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high confirmed objective res…
Clinical validation of PRAME as multi-tumor target with large potential for TCR-based therapies: confirmed responses in…